Cumberland Pharmaceuticals Inc. has announced the latest results from its Phase 2 FIGHT DMD trial evaluating ifetroban, an oral therapy for Duchenne muscular dystrophy (DMD) heart disease. These findings, which were presented at the Parent Project Muscular Dystrophy Annual Conference, demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patients. The trial results, featuring new pharmacokinetic and cardiac biomarker data, indicate potential improvements in heart function and reduction in cardiac damage markers. The complete presentation is available on Cumberland's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.